s
s
s
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody Fab fragment ranibizumab (Lucentis) using our range of ready-made anti-idiotypic antibodies.
Ranibizumab was created from the same parent mouse antibody as bevacizumab (Avastin); it has four amino acid exchanges in the heavy chain and one amino acid exchange in the light chain compared to bevacizumab. Some of our anti-ranibizumab antibodies also detect bevacizumab (Table 1).
Table 1. Antibodies Specific to Ranibizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Ranibizumab-VEGF-A Complex Specific Type 3 |
HCA304 |
AbD299281 |
Fab-FH4 |
1 |
PK ELISA antigen capture format |
|
Ranibizumab & Ranibizumab-VEGF-A Non-Inhibitory Type 2 |
HCA306 |
AbD29858 |
Fab-FH4 |
18 |
PK ELISA antigen capture format |
|
HCA316 |
AbD29858_hIgG1 |
Human IgG1 HRP |
18 |
PK ELISA antigen capture format |
||
HCA307 |
AbD298652 |
Fab-FH4 |
5 |
PK ELISA antigen capture format |
||
Ranibizumab Inhibitory Type 1 |
HCA305 |
AbD16746_hIgG13 |
Human IgG1 |
2 |
ADA control |
|
HCA185 |
AbD17976_hIgG1 |
Human IgG1 |
0.4 |
ADA control |
* Affinity measured in the monovalent Fab format
1 Also specific for the bevacizumab-VEGF-A complex
2 Also specific for bevacizumab and bevacizumab-VEGF-A complex
3 Also specific for bevacizumab
4 Monovalent Fab antibody DYKDDDDK- and His-6-tags
This Type 3 monovalent Fab antibody recognizes the ranibizumab-VEGF complex; it does not bind to ranibizumab or VEGF-A alone. It is suitable as a detection antibody in a pharmacokinetic (PK) antigen capture ELISA, enabling detection of free drug.
The type 2 anti-ranibizumab antibodies bind to the ranibizumab idiotope, but do not inhibit the binding of ranibizumab to VEGF-A. They are suitable as a detection antibody in a PK antigen capture ELISA.
The two Type 1 antibodies inhibit the binding of ranibizumab to its target VEGF-A, and therefore detect free drug. The antibodies are in fully human IgG1 format, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Ranibizumab PK antigen capture ELISA using antibody HCA304.
Schematic image of PK antigen capture ELISA with Type 3 antibody. Drug target (red), Fab fragment antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple).
Fig. 2. Ranibizumab PK antigen capture ELISA using antibody HCA307.
Schematic image of PK antigen capture ELISA with Type 2 antibody. Drug target (red), Fab fragment antibody drug (gold), non-inhibitory detection antibody, monovalent Fab format (purple).
Fig. 3. Ranibizumab PK antigen capture ELISA using antibody HCA316P.
Schematic image of PK antigen capture ELISA with Type 2 antibody. Drug target (red), Fab fragment antibody drug (gold), non-inhibitory detection antibody, Ig format (blue), labeled with HRP.
Fig. 4. Ranibizumab ADA bridging ELISA using antibody HCA305.
Schematic image of ADA bridging assay. Monoclonal Fab fragment antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.